3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Withdrawn
1
Sponsor Class
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Conditions
Paraparesis, Tropical Spastic
1
Opportunistic Infections
1
Neuritis
1
Leukemia-Lymphoma, Adult T-Cell
1
Inflammation
1
HTLV-I Infections
1
Epstein-Barr Virus Infections
1
Cytomegalovirus Infections
1
Coinfection
1
Acquired Immunodeficiency Syndrome
1
Interventions
Exercise
5
Vitamin D
3
Resistance Training
3
Omeprazole
3
Etanercept
3
Dexmedetomidine
3
Ascorbic Acid
3
salicylsalicylic acid
2
palbociclib
2
epigallocatechin gallate
2
XENP 1595
2
Tea
2
Tablets
2
Sufentanil
2
Probiotics
2
Nutrition Assessment
2
Morphine
2
Metformin
2
Ketorolac
2
Infliximab
2
Ibuprofen
2
Fish Oils
2
Endurance Training
2
Colchicine
2
Aspirin
2
soybean oil, phospholipid emulsion
1
montelukast
1
microcrystalline cellulose
1
ginger extract
1
falcarinol
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Inflammation
×
dolutegravir
×
Clear all
NCT04183738
2020-11-10
i2-D²EFT
Kirby Institute
Phase 4
Withdrawn